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Abstract
Melanoma is the leading cause of death from skin disease due, in large part, to its propensity to metastasize. We have
examined the effect of grape seed proanthocyanidins (GSPs) on melanoma cancer cell migration and the molecular
mechanisms underlying these effects using highly metastasis-specific human melanoma cell lines, A375 and Hs294t. Using
in vitro cell invasion assays, we observed that treatment of A375 and Hs294t cells with GSPs resulted in a concentration-
dependent inhibition of invasion or cell migration of these cells, which was associated with a reduction in the levels of
cyclooxygenase (COX)-2 expression and prostaglandin (PG) E2 production. Treatment of cells with celecoxib, a COX-2
inhibitor, or transient transfection of melanoma cells with COX-2 small interfering RNA, also inhibited melanoma cell
migration. Treatment of cells with 12-O-tetradecanoylphorbol-13-acetate, an inducer of COX-2, enhanced the
phosphorylation of ERK1/2, a protein of mitogen-activated protein kinase family, and subsequently cell migration whereas
both GSPs and celecoxib significantly inhibited 12-O-tetradecanoylphorbol-13-acetate -promoted cell migration as well as
phosphorylation of ERK1/2. Treatment of cells with UO126, an inhibitor of MEK, also inhibited the migration of melanoma
cells. Further, GSPs inhibited the activation of NF-kB/p65, an upstream regulator of COX-2, in melanoma cells, and treatment
of cells with caffeic acid phenethyl ester, an inhibitor of NF-kB, also inhibited cell migration. Additionally, inhibition of
melanoma cell migration by GSPs was associated with reversal of epithelial-mesenchymal transition process, which resulted
in an increase in the levels of epithelial biomarkers (E-cadherin and cytokeratins) while loss of mesenchymal biomarkers
(vimentin, fibronectin and N-cadherin) in melanoma cells. Together, these results indicate that GSPs have the ability to
inhibit melanoma cell invasion/migration by targeting the endogenous expression of COX-2 and reversing the process of
epithelial-to-mesenchymal transition.
Citation: Vaid M, Singh T, Katiyar SK (2011) Grape Seed Proanthocyanidins Inhibit Melanoma Cell Invasiveness by Reduction of PGE2 Synthesis and Reversal of
Epithelial-to-Mesenchymal Transition. PLoS ONE 6(6): e21539. doi:10.1371/journal.pone.0021539
Editor: Lin Zhang, University of Pennsylvania School of Medicine, United States of America
Received May 16, 2011; Accepted June 1, 2011; Published June 27, 2011
Copyright:  2011 Vaid et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by funds from the Veterans Administration Merit Review Award (SKK). There is no grant number. The funder had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: skatiyar@uab.edu
Introduction
Melanoma is the leading cause of death from skin disease due to
its propensity to metastasis [1,2], and is increasing rapidly in
children [3]. Although, melanoma is less common than other types
of skin cancers, it causes the majority (75%) of skin cancer-related
deaths [1,4]. The American Cancer Society estimated that in
2008, there were 8,420 melanoma-associated deaths in the U.S.
and the number of new cases of invasive melanoma was estimated
at 62,480 [1]. Solar ultraviolet (UV) radiation is a recognized risk
factor for the development of skin cancers, including melanoma.
Exposure of the skin to UV radiation induces an increase in the
expression levels of cyclooxygenase -2 (COX-2), a rate-limiting
enzyme that catalyzes the conversion of arachidonic acid to
prostaglandins (PGs) [5,6]. These inflammatory mediators have
been identified as a risk factor for the development of skin cancers
[5,6], and thought to play a central role in orchestrating the
multiple events involved in cancer invasion and metastasis [7,8].
Since, melanoma is a highly malignant cancer with a potent
capacity to metastasize distantly, an approach that decreases its
metastatic or invasive ability may facilitate the development of an
effective strategy for its treatment or prevention.
Dietary phytochemicals offer promising new options for the
development of more effective strategies for the prevention of cancer
cell invasion, migration, or metastasis, and thus can be utilized as
complementary and alternative medicine. Grape seed proanthocya-
nidins (GSPs) are promising phytochemicals that have shown anti-
carcinogenic effects in some murine models and exhibit no apparent
toxicity in vivo [9–11]. GSPs contain primarily proanthocyanidins
(89%), which constitute dimers, trimers, tetramers, and oligomers of
monomeric catechins and/or (-)-epicatechins, as described previously
[10]. They are readily available as an extract of grape seeds and this
extract, rather than the individual constituents, has been examined as
an anti-carcinogenic agent against some forms of cancers [9]. It is
believed that at least some of the constituents present in the extract
may act synergistically and thus this product can be more effective
than any single constituent. GSPs have been shown to inhibit UV
radiation-induced skin cancer in mouse model [10] but its
chemopreventive effect on the migration or invasive potential of
melanoma cancer cells has not been explored.
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21539In this study, we assessed the chemotherapeutic effects of GSPs
on the migration potential of human melanoma cells, as the
migration of cancer cells is a major event in the metastatic cascade.
For this purpose, two highly metastasis-specific melanoma cancer
cell lines were selected: one is A375 which is BRAF mutated and
activating mutations of the protooncogene BRAF have been
observed in approximately 50% of malignant melanomas. Second
cell line is Hs294t, which is also highly metastatic but not BRAF
mutated. In this study, we characterized the role of COX-2 and its
metabolite PGE2 on the migration of human melanoma cancer
cells and ascertained whether GSPs have any suppressive effects
on the COX-2-mediated migration of these cells. Epithelial-to-
mesenchymal transition (EMT), the process whereby epithelial
cells transform into mesenchymal cells, has recently been shown to
be relevant for cancer and cancer metastasis. During EMT, cancer
cells lose expression of proteins that promote cell-cell contact such
as E-cadherin and acquire mesenchymal markers such as
vimentin, fibronectin and N-cadherin, which promote cell
invasion and metastasis [12]. The EMT has also been associated
with higher levels of inflammation or inflammatory mediators, and
therefore we have also checked whether inhibition of COX-2
expression by GSPs in melanoma cells is associated with reversal of
EMT and that leads to inhibitory effect on melanoma cell
migration. Here, we present evidence that GSPs inhibit the
invasiveness or migratory behavior of melanoma cancer cells
through inhibition or reversal of EMT in melanoma cells and that
GSPs do so through a process that involves the reduction in COX-
2 expression and PGE2 production.
Materials and Methods
Source and composition of GSPs
GSPs were received from Kikkoman Corporation (Noda,
Japan). Quality control of GSPs is maintained by the company
on lot-to-lot basis. GSPs contain approximately 89% proantho-
cyanidins, with dimers (6.6%), trimers (5.0%), tetramers (2.9%)
and oligomers (74.8%), as described earlier [10,11], and are stable
for at least two years when refrigerated at 4uC.
Cell lines and cell culture conditions
The human melanoma cells lines, A375 and Hs294, were
purchased from the American Type Culture Collection (Manassas,
VA). The cell lines were cultured as monolayers in RPMI 1640
culture medium supplemented with 10% heat-inactivated fetal
bovine serum (Hyclone, Logan, UT), 100 mg/ml penicillin, and
100 mg/ml streptomycin and maintained in an incubator with 5%
CO2 at 37uC. The GSPs were dissolved in a small amount of
dimethylsulfoxide (DMSO), which was added to the complete cell
culture medium [maximum concentration of DMSO, 0.1% (v/v) in
media] prior to addition to sub-confluent cells (60–70% confluent).
Cells treated with DMSO only served as a vehicle control. Normal
human epidermal melanocytes (HEMa-LP, Cat. No. C-024-5C)
were commercially obtained from Invitrogen (Carlsbad, CA), and
were cultured in HMGS-2 medium supplemented with human
melanocyte growth supplement provided by the supplier. To
determine the effect of GSPs on 12-O-tetradecanoylphorbol-13-
acetate (TPA)- or PGE2-mediated effects, GSPs were added in cell
culture medium at least 30 minutes before the treatment of the cells
with TPA, PGE2 or any other agent.
Antibodies, chemicals and reagents
Antibodies specific for COX-2 and an enzyme immunoassay kit
for PGE2 analysis were obtained from Cayman Chemicals (Ann
Arbor, MI). Celecoxib, PGE2 and 12-O-tetradecanoylphorbol-13-
acetate (TPA) were purchased from Sigma Chemical Co. (St.
Louis, MO). Boyden Chambers and polycarbonate membranes
(8 mm pore size) for cell migration assays were obtained from
Neuroprobe, Inc. (Gaithersburg, MD). The antibodies specific to
N-cadherin, keratin-8, -18 and fibronectin were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA), while antibodies for
vimentin, E-cadherin, NF-kB, IKKa and IkBa were purchased
from Cell Signaling Technology (Beverly, MA) while desmoglein-2
was obtained from Abcam (Cambridge, MA). The secondary
antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 594
were purchased from Invitrogen (Carlsbad, CA).
Cell migration or invasion assay
The migration capacity of melanoma cancer cells was determined
in vitro using Boyden Chambers (Gaithersburg, MD) in which the two
chambers were separated with matrigel coated Millipore membranes
(6.5 mm diameter filters, 8 mM pore size), as detailed previously [13].
Briefly, melanoma cells (1.5610
4 cells/100 mL serum-reduced
medium) were placed in the upper chamber of Boyden chambers,
test agents were added alone, or in combination, to the upper (200 mL)
chamber, and the lower chamber contained the medium alone
(150 mL). Chambers were assembled and kept in an incubator for
24 h. After incubation, cells from the upper surface of Millipore
membranes were removed with gentle swabbing and the migrant cells
on the lower surface of membranes were fixed and stained with either
hematoxylin or crystal violet. Membranes were then washed with
distilled water and mounted onto glass slides. The membranes were
examined microscopically and cellular migration was determined by
counting the number of stained cells on membranes in at least 4–5
randomly selected fields using an Olympus BX41 microscope.
Representative photomicrographs were obtained using a Qcolor5
digital camera system fitted to an Olympus BX41 microscope. Each
cell migration experiment was repeated at least three times.
PGE2 immunoassay for quantitation of prostaglandin E2
The analysis of PGE2 in cell homogenates was performed using
the Cayman PGE2 Enzyme Immunoassay Kit (Ann Arbor, MI)
following the manufacturer’s instructions. Briefly, at indicated time
points, cells were harvested and homogenized in 100 mM
phosphate buffer, pH 7.4 containing 1 mM ethylenediamine
tetraacetic acid and 10 mM indomethacin using a homogenizer.
Homogenates were centrifuged and the supernatants were
collected and analyzed for PGE2 concentration according to the
manufacturer’s instructions.
COX-2-siRNA transfection of A375 and Hs294t cells
Human-specific COX-2 siRNA was transfected into A375 and
Hs294t cells using the siRNA Transfection Reagent Kit (Santa
Cruz Biotechnology, Inc.; Santa Cruz, CA) according to the
manufacturer’s protocol. Briefly, 2610
5 cells/well were seeded in a
6-well plate and allowed to grow to 70% confluency. The COX-2
siRNA mix with transfection reagents was overlaid on the cells for
approximately 6 h at 37uC and transferred into 26 growth
medium for about 18–20 h. At 24 h post-transfection, fresh
medium was added to the cells and the cells were incubated for an
additional 48 h. Thereafter, cells were harvested and subjected to
the cell migration assay. The knockdown of COX-2 expression in
cells after transfection was confirmed using western blot analysis.
NF-kB/p65 activity assay
For quantitative analysis of NF-kB/p65 activity, the NF-kB
Trans
AM Activity Assay Kit (Active Motif, Carlsbad, CA) was used
following the manufacturer’s protocol. For this purpose, the
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Extraction Kit (Active Motif, Carlsbad, CA) following the
manufacturer’s instructions, and as performed previously [14].
Absorbance was recorded at 450 nm using absorbance at 650 nm
as the reference. The results are expressed as the percentage of the
optical density of the non-GSPs-treated control group.
Preparation of cell lysates and western blot analysis
Following treatment of melanoma cells for the indicated time
periods with or without GSPs or any other agent, the cells were
harvested, washed with cold PBS and lysed with ice-cold lysis
buffer supplemented with protease inhibitors, as detailed previ-
ously [15]. Equal amounts of proteins were resolved on 10% Tris-
Glycine gels and transferred onto a nitrocellulose membrane. After
blocking the non-specific binding sites, the membrane was
incubated with the primary antibody at 4uC overnight. The
membrane was then incubated with the appropriate peroxidase-
conjugated secondary antibody and the immunoreactive bands
were visualized using the enhanced chemiluminescence reagents.
To verify equal protein loading, the membrane was stripped and
reprobed with anti-b actin antibody.
Immunofluorescent detection of EMT biomarkers in cells
In order to determine whether GSPs inhibit cell migration of
melanoma cells is associated with reversal of epithelial-to-mesen-
chymaltransition,the A375melanomacellswereeithertreatedwith
various concentrations of GSPs or celecoxib or TPA for 24 h. After
24 h, cells were harvested and cell lysates were prepared for western
blotting for the analysis of epithelial and mesenchymal biomarkers.
Cells were also used for cytostaining for the detection of EMT
biomarkers such as vimentin, fibronectin and N-cadherin. Briefly,
after harvesting the cells, cells were processed for cytospin (1610
5
cells/slide). Cells were fixed with chilled methanol at 220uC for
10 minutes and non specific binding sites were blocked with 2%
bovine serum albumin (Sigma, St. Louis, MO) in PBS for 30 min.
Cells were then incubated with antibodies specific to EMT
biomarkers for 2 h at room temperature. The cells were washed
with PBS and antigen was detected by an Alexa Fluor-conjugated
secondary antibody. Goat anti-rabbit IgG labeled with green-
fluorescent Alexa Fluor 488 dye was used for detection of N-
cadherin and vimentin, while donkey anti-mouse IgG labeled with
red-fluorescent Alexa Fluor 594 was used for the detection of the
expression of desmoglein 2. Cells were finally mounted with
Vectashield mounting medium for fluorescence with DAPI (Vector
Laboratories, Burlingame, CA) before they were observed under
fluorescence microscope and photographed.
Statistical analysis
For migration assays, the control and GSPs-, TPA- or PGE2-
treatment groups or combined-treatment groups separately were
compared using one-way analysis of variance (ANOVA) followed
by post hoc Dunn’s test using GraphPad Prism version 4.00 for
Windows, GraphPad Software, San Diego, California, USA,
www.graphpad.com. All quantitative data for cell migration are
shown as mean 6 SD/microscopic field. In each case P,0.05 was
considered statistically significant.
Results
Comparative invasiveness of human melanoma cells and
normal human epidermal melanocytes
First, we examined the migration capacity of melanoma cells and
compared this capacity with normal human epidermal melanocytes
under identical conditions. For this purpose, cells were incubated in
Boyden chambers for 24 h to assess their migration capability. As
shown in Figure 1A, the cell migration capacity of melanoma cells
was significantly higher (P,0.001) than normal human epidermal
melanocytes. The migration of A375 cells, which are BRAF
mutated, was greater (390614 cells/microscopic field) than
Hs294t cells (340612 cells/microscopic field), which are metasta-
sis-specific but not BRAF-mutated. Under identical conditions,
migration of normal human epidermal melanocytes was lower
(1964 cells/microscopic field) than melanoma cells.
GSPs inhibit human melanoma cancer cell migration
We determined whether treatment of A375 and Hs294t human
melanoma cells with GSPs inhibited their invasiveness or
migration using Boyden chamber cell migration assays. First,
screening experiments were performed to determine the effects of
lower concentrations of GSPs (mg/mL). The selection of the
concentrations of GSPs was based on consideration of their
relevance and achievability in vivo. As shown in Figure 1B, relative
to untreated control cells, treatment of cells with GSPs at
concentrations of 0, 10, 20 and 40 mg/mL reduced the invasive
potential of A375 and Hs294t cells in a concentration-dependent
manner. The density of the migrating cells on the membrane after
staining with crystal violet is shown in Figure 1B, and the numbers
of migrating cells/microscopic field are summarized in Figure 1C.
The cell migration was inhibited by 22 to 64% (P,0.0120.001) in
A375 cells and by 29–69% (P,0.0120.001) in Hs294t cells in a
concentration-dependent manner after treatment with GSPs for
24 h. A similar but comparatively higher inhibitory effect on cell
migration was observed at the 48 h time point (data not shown).
To confirm that the inhibition of cancer cell migration by GSPs
was a direct effect on migration ability, and that was not due to a
reduction in cell viability, a trypan blue assay was performed using
cells that were treated identically to those used in the migration
assays. Treatment of A375 and Hs294t cells with various
concentrations of GSPs (0, 10, 20 and 40 mg/mL) for 24 h had
no significant effect on cell viability or cell death (data not shown).
The inhibitory effect of GSPs on invasiveness of
melanoma cells is associated with the reduction of
endogenous COX-2 expression and reduction of PGE2
synthesis
To determine whether the inhibitory effect of GSPs on the
migration of the melanoma cells is associated with inhibition of
endogenous COX-2 expression, we determined the levels of
COX-2 in lysates of cells from the various treatment groups using
western blot analysis. As shown in Figure 2A, treatment of A375
and Hs294t cells with GSPs reduced the levels of COX-2
expression in a concentration-dependent manner as compared to
the expression in untreated controls. As the COX-2 metabolite,
PGE2, has been implicated in COX-2-mediated effects including
cancer cell metastasis; we determined the levels of PGE2 in the
GSPs-treated cells. Our results revealed that treatment with GSPs
for 24 h resulted in significant reduction in the production or
synthesis of PGE2 in both A375 (19–76%, P,0.001) and Hs294t
(18–71%, P,0.001) cells in a concentration-dependent manner
(Figure 2B), suggesting that GSPs-induced reduction in PGE2
production is associated with an inhibitory effect of the GSPs on
COX-2 expression and inhibition of cell migration in these cells.
Selective COX-2 inhibitor inhibits melanoma cell
migration
This experiment was performed to determine whether the
inhibitory effect of GSPs on melanoma cell migration is mediated
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equal numbers of A375 and Hs294t cells were subjected to the cell
migration assay after treatment with various concentrations of
celecoxib (0, 5, 10, 20 mM), a well known inhibitor of COX-2, for
24 h. As shown in Figure 2C, treatment of the cells with celecoxib
resulted in a dose-dependent reduction in the cell migration
capacity of melanoma cells as compared with non-celecoxib-treated
controls (P,0.0520.001). These data suggested that the inhibition
of constitutive levels of COX-2 expression is associated with the
inhibition of melanoma cell migration.
siRNA knock-down of COX-2 leads to reduction of
melanoma cell migration
We further verified the role of COX-2 in cell migration through
siRNA knock-down of COX-2 in the melanoma cells and
examined whether it would lead to the inhibition of the cell
migration in these cells. The transfection of A375 and Hs294t cells
with COX-2 siRNA resulted in significant reduction of cell
migration in A375 (85%, P,0.001) and Hs294t (86%, P,0.001)
cells after 24 h as compared to the migration of control siRNA-
transfected A375 and Hs294t cells (Figure 2D).
GSPs inhibit PGE2-induced cell migration of melanoma
cells
As the effects of COX-2 are mediated through its metabolites,
such as PGE2, we examined whether GSPs inhibit PGE2-induced
cell migration in human melanoma cells. For this purpose, A375
and Hs294t cells were treated with PGE2 (10 mM) with and
without GSPs for 24 h and cell migration determined. We found
that the treatment of melanoma cells with PGE2 resulted in a
significant increase in cell migration (P,0.05) compared to the
cells which were not treated with PGE2 (Figure 2E). Treatment of
A375 and Hs294t cells with GSPs (20 or 40 mg/mL) resulted in a
dose-dependent inhibition of PGE2 (10 mM)-induced cell migra-
tion (Figure 2E). As the inhibitory effect of GSPs on the migration
of A375 and Hs294t cell lines was very similar, the subsequent
studies were performed only with A375 cells.
TPA, an inducer of COX-2, enhances melanoma cell
migration, and GSPs inhibit TPA-induced cell migration
Treatment of skin with TPA stimulates the levels of COX-2
expression [11,16]; therefore, the melanoma cells were treated with
Figure 1. Effect of GSPs on melanoma cell migration. (A) Migration ability of human melanoma cells and comparison with normal human
epidermal melanocytes (HEMa). Equal numbers of human melanoma cells (A375 and Hs294t) and HEMa were subjected to cell migration using
standard Boyden chamber assay. Twenty four h later, migratory cells were detected on the membrane after staining with crystal violet. The migratory
cells were counted and the results expressed as the mean number of migratory cells 6 SD per microscopic field (n=3). Significantly lower versus
melanoma cells,
*P,0.001. (B) Treatment of human melanoma cancer cells (A375 and Hs294t) with GSPs for 24 h inhibit migration of cells in a
concentration-dependent manner compared to non-GSPs-treated control cells. (C) The migratory cells were counted and the results expressed as the
mean number of migratory cells 6 SD/microscopic field. Significant inhibition versus non-GSPs-treated control,
*P,0.001.
doi:10.1371/journal.pone.0021539.g001
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TPA on the migration of melanoma cells. As shown in Figure 3A,
treatment of A375 cells with TPA for 24 h resulted in significantly
enhanced cell migration (P,0.01) compared to non-TPA-treated
cells. To determine whether GSPs inhibit TPA-induced cell
migration in human melanoma cells, A375 cells were treated with
TPA (40 ng/mL) with and without the treatment of GSPs for 24 h.
We found that the treatment of A375 cells with GSPs resulted in a
dose-dependent inhibition of TPA-induced cell migration. A
summary of the cell migration data for the various treatment
groups is providedinFigure 3A.Treatment of cells with GSPs at the
doses of 20 mg/mL and 40 mg/mL inhibited TPA-induced cell
migration by 50% (P,0.01) and .100% (P,0.001) respectively.
GSPs and celecoxib inhibit TPA-induced activation of
ERK1/2 protein in melanoma cells
As activation of MAPK proteins has been implicated in the
enhancement of COX-2 expression or an upstream regulator of
COX-2, we examined the effect of TPA on activation of ERK1/2
in melanoma cells, and simultaneously checked the effect of GSPs
or celecoxib on TPA-induced activation of ERK1/2. Western blot
analysis revealed that treatment of A375 cells with TPA enhanced
the activation of ERK1/2, however, treatment of cells with GSPs
or celecoxib inhibited TPA-induced activation of ERK1/2, as
shown in Figure 3B. We further checked the effect of GSPs and
celecoxib on TPA-induced cell migration. Cell migration assay
analysis revealed that both GSPs and celecoxib significantly
inhibited TPA-induced cell migration of melanoma cells
(Figure 3C). We further verified the role of activated ERK1/2 in
melanoma cell migration by using the inhibitor of MEK (UO126).
Cell migration assay revealed that treatment of A375 cells with
UO126 significantly inhibited (P,0.001) melanoma cell migration
(Figure 3D). A summary of data related with cell migration are
also shown. Additionally, western blot analysis revealed that the
level of activated ERK1/2 was also decreased after the treatment
of cells with MEK inhibitor UO126, as shown in Figure 3D.
GSPs decrease the activation of NF-kB/p65 in melanoma
cells: NF-kB is an important mediator of melanoma cell
migration
COX-2 is a downstream target of NF-kB, therefore we assessed
whether GSPs also affect the proteins of NF-kB family in
melanoma cells. For this purpose, A375 cells were treated with
various concentrations of GSPs (0, 10, 20 and 40 mg/mL) for 24 h,
and thereafter cells were harvested and whole cell lysates and
nuclear lysates were prepared. The results of western blot analysis
revealed that treatment of cells with GSPs reduce the nuclear
translocation of NF-kB/p65 in a dose-dependent manner
(Figure 4A). The activity of NF-kB also was significantly reduced
(25–70%, P,0.01 and P,0.001) after the treatment of cells with
GSPs in a concentration-dependent manner (Figure 4B). The
western blot analysis also revealed that treatment of GSPs resulted
in the down-regulation of IKKa, an enzyme responsible for NF-
kB activation, and degradation of IkBa (Figure 4A), which leads to
the inactivation of NF-kB. To check whether NF-kB has a role in
melanoma cell migration, A375 melanoma cells were treated with
caffeic acid phenethyl ester (0, 5, 10 and 20 mg/mL), a potent
inhibitor of NF-kB, and cell migration was determined. As shown
in Figure 4C, treatment of cells with caffeic acid phenethyl ester
resulted in a dose-dependent reduction of cell migration (24–78%)
relative to untreated control cells, and it was similar to that
observed on treatment of the cells with GSPs (Figure 1B).
GSPs reverse epithelial-to-mesenchymal transition in
melanoma cells
Activation of NF-kB has been implicated in inflammation-
induced cancer development and progression, and has been
identified as an important regulator of EMT in several cancer cell
types [17–20]. As the inhibition of melanoma cell migration by
GSPs is associated with the inactivation of NF-kB, we sought to
determine whether GSPs also affect or reverse EMT in melanoma
Figure 2. Effect of GSPs on COX-2 expression, PGE2 production
and cell migration in melanoma cells. (A) Effect of GSPs on the
endogenous basal level of COX-2 in A375 and Hs294t cells. The levels of
COX-2 were determined in cell lysates using western blot analysis. (B)
Dose-dependent effect of GSPs on the levels of PGE2 in melanoma cells.
The levels of PGE2 are expressed in terms of pg/mg protein6 SD, n=3
independent experiments. Significant inhibition of PGE2 level by GSPs
versus non-GSPs-treated controls,
*P,0.001. (C) Down-regulation of
endogenous COX-2 reduces melanoma cell migration. Treatment of
A375 and Hs294t cells with celecoxib, a COX-2 inhibitor, inhibits cell
migration in a dose-dependent manner. Significant difference versus
control (non-celecoxib-treated) cells,
"P,0.05,
*P,0.001. (D) Transfec-
tion of cells, both A375 and Hs294t, with COX-2 siRNA significantly
decreases cell migration. A375 and Hs294t cells were transfected with
COX-2 siRNA to knockdown COX-2 expression. Significant reduction of
cell migration versus control siRNA-treated cells:
*P,0.001. (E)
Treatment of A375 and Hs294t cells with GSPs (20 and 40 mg/mL)
inhibits PGE2-enhanced cell migration. The data on cell migration are
summarized as a mean number of migratory cells 6SD/microscopic
field. In each case, the migrating cells were counted at 4–5 different
microscopic fields, and data are expressed as the mean number of
migratory cells6 SD/microscopic field, n=3.
doi:10.1371/journal.pone.0021539.g002
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invasiveness. For this purpose, A375 cells were treated with GSPs
for 24 h, and cell lysates were prepared for the western blot analyses
of various epithelial and mesenchymal biomarkers. Our western
blot analyses revealed that GSPs restored or increased the levels of
the epithelial biomarkers, such as E-cadherin, keratin-18, keratin-8
and desmoglein 2 in melanoma cells compared to untreated
controls. In contrast, the levels of mesenchymal biomarkers, such as
N-cadherin, vimentin, fibronectin and SLUG, were reduced in
melanoma cells after treatment with GSPs in a dose-dependent
manner, asshown inFigure5A.GSPs-inducedchanges or effectson
these epithelial and mesenchymal biomarkers were also detected
and analyzed using immunofluorescence staining (Figure 5B).
Immunofluorescnce staining data revealed that treatment of A375
cells with GSPs for 24 h resulted in reduction of mesenchymal
biomarkers, such as vimentin, fibronectin and N-cadherin which is
evident by the intensity of staining of the cells. In contrast, GSPs
enhanced the levels of epithelial biomarker, suchas desmoglein 2, in
melanoma cells which is evident by the strong intensity of
fluorescence staining compared to untreated controls. Similar
Figure 3. Effect of GSPs and celecoxib on TPA-induced
activation of ERK1/2 and melanoma cell migration. (A) Effect
of TPA or its combination with GSPs on melanoma cell migration.
Treatment of A375 cells with TPA, a stimulator of COX-2, significantly
enhances cell migration (
{P,0.001) compared with non-TPA-treated
control cells. (B&C ) Treatment of A375 cells with TPA results in
activation of ERK1/2. Treatment of cells with GSPs (40 mg/mL) or
celecoxib (40 mM) inhibits TPA-induced activation of ERK1/2 protein,
and simultaneously inhibits TPA-enhanced migration of melanoma
cells. The data on cell migration capacity are summarized in Panel C.
Significant inhibition versus TPA-treatment alone,
*P,0.001. (D)
Treatment of melanoma cells with MEK inhibitor (UO126, 80 mM)
resulted in inhibition of the activation of ERK1/2 as well as inhibition of
cell migration compared to non-MEK inhibitor-treated control cells. The
data are expressed as the mean number of migratory cells6 SD/
microscopic field, n=3. Significant difference versus controls
*P,0.001.
doi:10.1371/journal.pone.0021539.g003
Figure 4. Effect of GSPs on NF-kB activation. (A) Treatment of
A375 cells with GSPs decreases the basal levels of NF-kB/p65 and IKKa
while inhibiting the degradation of IkBa. After treatment of cells for
24 h with various concentrations of GSPs the cells were harvested and
cytosolic and nuclear fractions were prepared and subjected to the
analysis of NF-kB/p65, IKKa and IkBa using western blot analysis.
Representative blot is shown from three independent experiments with
identical results. (B) The activity of NF-kB/p65 in the nuclear fraction of
cells after treatment with and without GSPs for 24 h was measured
using NF-kB/p65-specific activity assay kit, n=3. Activity of NF-kB/p65 is
expressed in terms of percent of control (non-GSPs-treated) group.
Significant decrease versus control:
"P,0.01,
*P,0.001. (C) Treatment
of A375 cells with caffeic acid phenethyl ester (CAPE), an inhibitor of NF-
kB, for 24 h inhibits cell migration in a concentration-dependent
manner. Data on cell migration capacity are summarized as the mean
number of migratory cells 6 SD/microscopic field, n=3. Significant
inhibition versus non-CAPE-treated cells:
*P,0.001.
doi:10.1371/journal.pone.0021539.g004
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a COX-2-specific inhibitor, in identical manner. Representative
photomicrographs are shown from three independent experiments.
GSPs and celecoxib inhibit TPA-induced EMT biomarkers
in melanoma cells
As TPA induces COX-2 expression as well as enhances cell
migration in melanoma cells, we next examined whether TPA
promotes EMT in melanoma cells and whether GSPs and
celecoxib inhibit TPA-induced EMT in these cells. For this
purpose, A375 melanoma cells were treated with either TPA or
celecoxib alone or TPA with the treatment of GSPs for 24 h, cell
lysates prepared and subjected to western blot analysis. As shown
in Figure 6, TPA decreased the level of desmoglein 2 (an epithelial
biomarker), while enhanced the levels of mesenchymal biomarkers
(N-cadherin and vimentin) compared with untreated control cells.
Celecoxib enhanced the level of desmoglein 2 while decreased the
levels of N-cadherin and vimentin compared with untreated
control melanoma cells. Further, as shown in Figure 6, GSPs
increased or restore the level of desmoglein 2 in TPA-treated
melanoma cells, while reduced TPA-induced levels of N-cadherin
and vimentin on A375 cells. These data further support the
evidence that GSPs function as a COX-2 inhibitor and have the
ability to reverse EMT in melanoma cancer cells and thus lead to
reduce the invasiveness of melanoma cells.
Discussion
Melanoma cells can metastasize rapidly and that is the leading
cause of death. According to a World Health Organization report,
48,000 melanoma-related deaths occur worldwide per year [21].
Figure 5. Treatment of melanoma cells with GSPs results in reversal of epithelial to mesenchymal transition. (A) Treatment of A375
cells with GSPs for 24 h enhances the levels of epithelial biomarkers in the cells, such as, the levels of E-cadherin, keratin-18, keratin-8 and desmoglein
2. Simultaneously the levels of mesenchymal biomarkers in melanoma cells, such as, vimentin, fibronectin, N-cadherin and SLUG were decreased
dose-dependently. (B) Identification of the levels of epithelial and mesenchymal biomarkers in A375 cells after the treatment of cells with GSPs or
celecoxib using immunocytostaining, as detailed in Materials and Methods. Treatment of A375 cells with GSPs (20 and 40 mg/mL) or celecoxib
(20 mM) for 24 h resulted in reduced expression of vimentin, fibronectin and N-cadherine, while the level of desmoglein 2 was increased.
Representative photomicrographs are representative of three independent experiments with similar results.
doi:10.1371/journal.pone.0021539.g005
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nodes [22]. Therefore, innovative strategies are required to be
developed for the prevention of the invasive or the migratory
potential of melanoma cells. Many human cancers express
elevated levels of COX-2 and enhanced biosynthesis of PGs.
COX-2 overexpression and abundant production of PGs, and
particularly PGE2, have been linked with tumor progression,
invasion and metastasis [23]. Because of its important role in
tumor invasion and metastasis, COX-2 is always a promising
target for cancer therapy [8,24]; therefore, the search and
development of potential COX-2 as well as PGE2 inhibitors for
the prevention or treatment of melanoma may prove to be an
important and effective strategy.
The significant findings in the present study are that the
treatment of melanoma cells with GSPs inhibits cell migration in a
dose-dependent manner, and that is associated with the inhibition
of COX-2 expression and PGE2 production. The melanoma cells
overexpress COX-2, and the inhibition of COX-2 by GSPs
contributes to the inhibition of cell migration of these cells. This
concept is supported by the evidence that treatment of the
melanoma cells with celecoxib, a potent COX-2 inhibitor, resulted
in a reduction in cell migration. Similar effects were also noted
when the melanoma cancer cells, A375 and Hs294t, were
transfected with COX-2 siRNA. It has been shown that TPA
promotes COX-2 expression, and we found that treatment of
melanoma cells with TPA enhances cell migration, and that this
TPA-induced cell migration was blocked by the treatment of cells
with GSPs. These observations support the evidence that
inhibition of melanoma cell migration by GSPs requires the
inhibition of COX-2 expression. It has been reported that COX-2
inhibitors can inhibit cell migration; however, they may also
induce some form of toxicity. This possibility is not found in GSPs
as these are dietary components and toxicity has not been
observed in animal models [10,11].
It is well known that PGE2 exerts its biologic functions by
stimulating epithelial cell growth, invasion potential and cellular
survival signals [25,26]. Singh et al. [27] have shown that PGE2
treatment enhanced melanoma cell migration and that berberine,
a phytochemical, inhibits PGE2-induced migration of melanoma
cells. Punathil and Katiyar [28] have examined the effect of GSPs
on non-small cell lung cancer cell migration, and found that GSPs
inhibit the migration of these cells by targeting nitric oxide,
guanylate cyclase and ERK1/2 pathways. As COX-2 is a
downstream target of NF-kB pathway, we further checked the
effect of GSPs on the basal levels of NF-kB in melanoma cells, and
found that treatment of melanoma cells with GSPs results in
inactivation of NF-kB pathway in a dose-dependent manner.
GSPs down-regulate the levels of IKKa which is responsible for
NF-kB activation. Treatment of melanoma cells with caffeic acid
phenethyl ester, an inhibitor of NF-kB, resulted in an inhibitory
effect on melanoma cell migration. These observations support the
concept that the inhibitory effect of GSPs on melanoma cell
migration is mediated through the downregulation of COX-2 and
PGE2, which are the downstream targets of NF-kB. Our study also
demonstrates the requirement of activated ERK1/2 in melanoma
cancer cell migration. Our results show that inhibition of
melanoma cell migration by GSPs is associated with the inhibition
of ERK1/2 phosphorylation. The inhibition of MEK with
UO126, a MEK inhibitor, blocked the migration capacity of
melanoma cells which is similar to the action of GSPs. Treatment
of A375 cells with TPA increased ERK1/2 phosphorylation and
subsequently enhanced cell migration, while treatment of cells with
celecoxib decreased ERK1/2 phosphorylation and subsequently
decreased cell migration. These observations suggest a possible
involvement of MAPK pathway (which is an upstream regulator of
NF-kB) in inhibition of melanoma cell migration by GSPs.
The transcription factor NF-kB regulates a wide spectrum of
biological processes, including inflammation, cell proliferation and
apoptosis. Additional roles of NF-kB in cancer biology, such as in
tissue invasion, cell migration and metastasis, have been
investigated recently. Importantly, NF-kB is involved in inflam-
mation-induced cancer development, and has been identified as an
important regulator of EMT in several cancer cell types [17–20].
EMT has been observed to play a major role in invasion and
metastasis of epithelial tumors. EMT can render tumor cells
migratory and invasive through the involvement of all stages,
invasion, intravasation and extravasation [12]. During the process
of EMT, cells can change from an epithelial to a mesenchymal
state. They lose their characteristic epithelial traits and instead
gain properties of mesenchymal cells. This process is primarily
coordinated by the disappearance or loss of epithelial biomarkers
such as E-cadherin and certain cytokeratins with the concomitant
appearance or gain of mesenchymal markers such as vimentin,
fibronection and N-cadherin, etc. In the present study, GSPs
treatment of melanoma cells showed the suppression of mesen-
chymal biomarkers, such as vimentin, fibronectin and N-cadherin
while restored the levels of epithelial biomarkers such as, E-
cadherin, desmoglein 2, keratin-8 and -18, etc, in melanoma cells
which suggest that GSPs have the ability to reverse the EMT
process in melanoma cells and this may also be one of the possible
mechanisms through which GSPs reduce the invasiveness of
melanoma cells and that lead to inhibition of melanoma cell
migration in our system.
Insummary,the results fromthisstudyhaveidentified forthe first
time that GSPs inhibit the invasiveness of melanoma cells or inhibit
the ability of melanoma cell migration and that involves: (i) the
inhibitory effect of GSPs on endogenous COX-2 overexpression
and successive down-regulation of PGE2 synthesis, (ii) the inhibitory
effect of GSPs on the activation of NF-kB and the proteins of
MAPK family, which are the upstream regulators of COX-2 and
PGE2, and (iii) the reversal of EMT process. More detailed studies
areneededtodevelopGSPsasapharmacologicallysafe agenteither
alone or in combination with other anti-metastatic drugs for the
treatment of metastatic melanoma in humans.
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Figure 6. The effect of GSPs, TPA and celecoxib on the EMT
biomarkers in melanoma cells. A375 cells were treated for 24 h and
cell lysates were prepared for the analysis of N-cadherin, vimentin and
desmoglein 2 using western blot analysis. Equal loading of proteins on
the membranes were verified using b-actin antibody. Representative
blots are shown from 3 independent experiments.
doi:10.1371/journal.pone.0021539.g006
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